Lifecore Biomedical, Inc. LFCR R2K
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
READ MORE ›$5.02
-25.85% 1Y
Market & Price
Market Cap
$188.30M
Current Price
$5.02
High / Low (52W)
$8.82 / $3.66
Beta
1.08
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
2.66
Book Value
$-0.38
Price to Book
-13.25
P/S
1.45
EV/EBITDA
44.51
Dividend Yield
-
Profitability & Returns
ROCE
-7.91%
ROE
-
ROA
-
Profit Margin
-23.78%
Op Margin
-13.25%
EPS (Latest Qtr)
$-0.43
EPS (TTM)
$-1.27
Balance Sheet & Liquidity
Debt/Equity
7.23
Quick Ratio
2.18
Current Ratio
3.49
Debt
$150.14M
Total Assets
$232.18M
Current Assets
$82.29M
Working Capital
$58.72M
Ownership
Promoter Holding
2.28%
Chg in Prom Hold
-
FII / Inst Holding
77.18%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$366.86M
Total Revenue (TTM)
$129.46M
EBITDA
$8.24M
Free Cash Flow
-
Operating Cash Flow
$12.57M
Shares Outstanding
37.51M
Gross Margin
31.37%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
5.02%
Profit 5Y
22.28%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- Profit CAGR of 22.3% over 5 years.
CONS
- Trading 43.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFCR Lifecore Biomedical, Inc. R2K | 5.02 | - | $188.30M | - | -7.91% | - | 5.02% | 22.28% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Nov 2015 | Feb 2016 | May 2016 | Aug 2016 | Nov 2016 | Feb 2017 | May 2017 | Aug 2017 | Nov 2017 | Feb 2018 | May 2018 | Aug 2018 | Nov 2018 | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | May 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 109.06M | 110.16M | 129.29M | 121.27M | 115.78M | 122.46M | 144.91M | 141.08M | 124.67M | 124.56M | 155.55M | 152.78M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.56M | 35.15M | 36.44M | 31.11M | 23.19M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.48M | 25.31M | 22.46M | 23.32M | 18.73M |
| Gross Profit | 17.27M | 12.93M | 22.78M | 20.12M | 17.10M | 22.87M | 19.12M | 18.80M | 14.92M | 19.81M | 24.81M | 16.34M | 16.89M | 21.57M | 26.21M | 15.34M | 15.51M | 20.05M | 24.09M | 5.29M | 10.77M | 10.93M | 14.58M | 5.54M | 11.46M | 11.64M | 10.42M | 5.98M | 5.68M | 8.55M | 7.78M | 2.73M | 9.96M | 11.89M | - | 11.08M | 9.85M | 13.98M | 7.79M | 4.46M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.04M | 12.02M | 11.08M | 10.86M | 9.13M |
| Operating Income | 2.81M | -33.62M | - | 5.47M | 3.26M | 4.33M | - | 2.73M | -695.00K | 3.48M | - | -257.00K | 10.00K | 3.24M | - | -4.38M | -6.04M | -15.01M | - | -10.60M | 1.37M | 73.00K | - | -4.22M | 3.69M | -9.64M | - | -3.27M | -5.35M | -6.53M | - | -8.61M | -1.48M | -895.00K | - | -1.96M | -2.18M | 2.90M | -3.07M | -4.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 981.00K | -7.11M | 6.32M | -1.29M | -5.28M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.46M | 5.59M | 5.52M | 6.38M | 7.35M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.53M | -14.78M | -1.11M | -9.66M | -14.94M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.00K | -8.00K | 33.00K | 333.00K | 43.00K |
| Net Income | 1.87M | -21.19M | 4.73M | 3.31M | 1.33M | 3.50M | 2.45M | 2.15M | 487.00K | 16.09M | 6.11M | 190.00K | -584.00K | 1.07M | -262.00K | -4.78M | -6.74M | -11.52M | -15.15M | -12.41M | -11.62M | -6.98M | - | -9.39M | -38.47M | -13.59M | - | -10.97M | -12.81M | -36.51M | - | -10.75M | 14.22M | 15.63M | - | -6.57M | -14.77M | -1.15M | -9.99M | -14.98M |
| Diluted EPS | 0.07 | -0.78 | 0.17 | 0.12 | 0.05 | 0.13 | 0.09 | 0.08 | 0.02 | 0.57 | - | 0.01 | -0.02 | 0.04 | - | -0.16 | -0.23 | -0.39 | - | -0.42 | -0.40 | -0.24 | - | -0.32 | -1.31 | -0.46 | -1.88 | -0.37 | -0.43 | -1.20 | -1.32 | -0.35 | 0.39 | 0.42 | - | -0.25 | -0.47 | -0.06 | -0.29 | -0.43 |
| R&D Expense | 1.64M | 1.90M | - | 1.94M | 1.97M | 2.01M | - | 2.72M | 3.37M | 3.11M | - | 2.79M | 2.48M | 2.74M | - | 2.82M | 2.82M | 2.75M | - | 1.74M | 1.59M | 1.64M | - | 1.69M | 1.68M | 2.25M | - | 2.21M | 2.18M | 2.23M | - | 2.15M | 2.10M | 2.17M | 2.19M | 1.92M | 2.04M | - | 1.96M | 1.22M |
Profit & Loss (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238.22M | 276.73M | 317.55M | 441.71M | - | - | 476.92M | 469.78M | 524.23M | 557.56M | - | - | 111.27M | 103.27M | 128.26M | 128.87M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 72.20M | 75.28M | 86.41M | 88.57M |
| Gross Profit | 33.77M | 46.70M | 52.14M | 62.76M | 62.56M | 65.41M | 66.78M | 79.21M | 78.34M | 81.00M | 39.39M | - | 39.07M | 27.98M | 41.85M | 40.30M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 42.50M | 47.70M | 49.04M | 52.30M |
| Operating Income | 7.98M | 8.03M | 14.58M | 24.87M | 20.19M | 18.46M | -20.63M | 14.67M | 13.59M | 5.47M | -25.88M | - | -3.43M | -19.72M | -7.19M | -12.01M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 12.84M | -33.17M | 35.62M | -8.48M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 15.47M | 17.58M | 18.15M | 22.17M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -20.69M | -63.93M | 9.51M | -38.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | -5.21M | 308.00K | 183.00K | 43.00K |
| Net Income | 3.98M | 3.92M | 12.70M | 22.59M | 19.14M | 13.54M | -11.64M | 10.59M | 24.83M | 411.00K | -38.19M | - | -116.72M | -99.56M | 12.01M | -38.72M |
| Diluted EPS | 0.15 | 0.15 | 0.49 | 0.85 | 0.71 | 0.50 | -0.43 | 0.38 | 0.89 | 0.01 | -1.31 | - | -3.30 | -3.41 | 0.32 | -1.27 |
| R&D Expense | 4.36M | 9.28M | 9.62M | 9.29M | 7.20M | 6.99M | 7.23M | 9.47M | 12.80M | 11.47M | 7.58M | 6.68M | 7.84M | 8.74M | 8.57M | 8.26M |
Compounded Sales Growth
| 5 Years: | 5.02% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 22.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -25.85% |
| 6 Months: | -36.46% |
| 3 Months: | -30.28% |
| 1 Month: | +1.62% |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2009 | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | May 2022 | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | May 2024 | May 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 206.31M | 277.69M | 290.94M | 313.62M | 346.46M | 342.65M | 358.61M | 404.70M | 519.09M | 293.50M | 503.04M | 498.07M | 506.86M | - | 444.73M | 421.31M | 324.24M | - | 266.38M | 275.97M | 236.66M | 253.54M | 253.96M | 239.34M | 232.18M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.88M | 81.03M | 85.68M | 82.29M |
| Cash & Equivalents | 43.46M | 27.82M | 8.13M | 22.18M | 13.72M | 14.24M | 14.13M | 9.97M | 6.00M | 2.90M | 1.08M | 360.00K | 439.00K | 2.48M | 1.85M | - | 939.00K | 609.00K | 1.10M | - | 2.54M | 5.94M | 2.95M | 19.09M | 8.46M | 8.27M | 17.47M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.84M | 39.98M | 32.29M | 29.09M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.02M | 27.08M | 28.69M | 26.16M |
| Total Liabilities | - | - | 68.59M | 126.13M | 110.53M | 108.86M | 126.36M | 130.30M | 130.46M | 152.14M | 248.95M | 310.27M | 284.50M | 290.07M | 304.66M | - | 251.61M | 265.88M | 181.68M | - | 188.50M | 204.83M | 163.10M | 257.77M | 242.65M | 238.01M | 246.38M |
| Current Liabilities | - | - | 30.70M | 66.68M | 50.75M | 48.39M | 56.16M | 56.34M | 51.45M | 88.38M | 137.09M | 164.39M | 153.69M | 173.88M | 125.31M | - | 103.65M | 122.39M | 90.40M | - | 178.74M | 195.62M | 37.40M | 39.29M | 38.87M | 30.18M | 23.57M |
| Long Term Debt | - | - | 15.50M | 40.30M | 34.37M | 28.32M | 34.17M | 45.97M | 42.30M | 37.36M | 87.19M | 101.36M | 93.92M | 82.00M | 145.05M | - | 123.83M | 124.19M | 79.60M | - | - | - | 98.90M | 101.06M | 123.72M | 127.00M | 135.59M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 112.62M | 128.63M | 130.82M | 142.61M |
| Total Equity | - | - | 136.06M | 149.74M | 178.69M | 203.07M | 218.43M | 210.73M | 226.61M | 252.56M | 270.14M | 229.84M | 218.54M | 208.00M | 202.20M | - | 193.12M | 155.42M | 142.56M | - | 77.88M | 71.14M | 35.02M | -4.23M | 11.31M | 1.34M | -14.20M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.51M | 30.56M | 37.03M | 37.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.48M | 14.47M | 22.18M | 21.23M | - | - | 20.76M | 29.84M | 19.78M | 16.02M | -17.04M | - | -22.59M | -17.44M | 257.00K | -206.00K |
| Investing Cash Flow | -42.80M | -29.39M | -44.07M | -10.42M | - | - | -40.42M | -25.42M | -35.59M | -96.80M | -23.89M | - | 79.96M | -4.81M | -18.39M | -6.42M |
| Financing Cash Flow | 19.67M | -4.76M | 35.93M | -19.27M | - | - | 15.42M | -8.80M | 13.29M | 79.03M | 40.02M | - | -57.02M | 39.70M | 7.51M | 6.42M |
| Capital Expenditure | -5.19M | -6.68M | -5.37M | -8.88M | -14.89M | -17.51M | -39.70M | -23.00M | -33.59M | -44.73M | -12.21M | - | -29.94M | -21.48M | -18.39M | -13.41M |
| Free Cash Flow | 2.29M | 7.79M | 16.81M | 12.35M | - | - | -18.93M | 6.83M | -13.81M | -28.71M | -29.25M | - | -52.53M | -38.92M | -18.14M | -13.62M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | 348.00K | 17.45M | -10.63M | -197.00K |
| Share Buybacks | - | 1.18M | 5.01M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 14.2% | 16.9% | 16.4% | 14.2% | - | - | 14.0% | 16.9% | 14.9% | 14.5% | - | - | 35.1% | 27.1% | 32.6% | 31.3% |
| Operating Margin % | 3.4% | 2.9% | 4.6% | 5.6% | - | - | -4.3% | 3.1% | 2.6% | 1.0% | - | - | -3.1% | -19.1% | -5.6% | -9.3% |
| Net Margin % | 1.7% | 1.4% | 4.0% | 5.1% | - | - | -2.4% | 2.3% | 4.7% | 0.1% | - | - | -104.9% | -96.4% | 9.4% | -30.0% |
| ROE % | - | 2.9% | 8.5% | 12.6% | 9.4% | 6.2% | -5.5% | 4.7% | 9.8% | 0.2% | -16.6% | - | - | 2,353.7% | 106.2% | -2,898.0% |
| ROCE % | - | 4.6% | 6.9% | 10.4% | 7.6% | 6.4% | -7.2% | 4.8% | 4.3% | 1.4% | -20.0% | - | - | -9.2% | -3.3% | -5.7% |
Shareholding Pattern
Insiders
2.28%
Institutions
77.18%
Public Float
78.98%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | WYNNEFIELD CAPITAL INC | 12.54% | 4.70M | $23.61M |
| 2 | Legion Partners Asset Management, LLC | 11.90% | 4.46M | $22.40M |
| 3 | Greenhaven Road Investment Management, L.p. | 9.43% | 3.54M | $17.76M |
| 4 | 325 Capital Llc | 5.77% | 2.16M | $10.86M |
| 5 | Blackrock Inc. | 5.00% | 1.88M | $9.42M |
| 6 | Vanguard Capital Management LLC | 3.44% | 1.29M | $6.48M |
| 7 | Grizzlyrock Capital, LLC | 2.21% | 827.49K | $4.15M |
| 8 | Geode Capital Management, LLC | 2.17% | 815.11K | $4.09M |
| 9 | Morgan Stanley | 2.04% | 764.73K | $3.84M |
| 10 | State Street Corporation | 1.71% | 642.01K | $3.22M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFCR
No recent headlines available.